Magnetic stimulation of the pelvic floor found not effective in the control of urinary incontinence. A study was conducted to determine the safety and effectiveness of non-invasive static magnetic stimulation (SMS) of the pelvic floor compared to placebo in the treatment of women aged 60 years and over with urinary incontinence in Australia.
Last week, in one of TV ad Actor Michael J. Fox appeared with his disturbingly uncontrolled movements. And, his opponents in the stem-cell debate accused him of either acting or purposefully not taking his medications, in an effort to gain sympathy, quoted by news agencies worldwide. Nothing could be further from the truth, according to Parkinson’s experts. In fact, Fox’s disordered movement — a condition called dyskinesia — was mainly due to his taking medication to help control his Parkinson’s, they said.
Mayo Clinic Cancer Center has opened a new clinical study using a vaccine strain of the measles virus to attack recurrent glioblastoma multiforme, a largely untreatable brain tumor. This is the second of several pending molecular medicine studies in patients using measles to kill cancer.
Bristol-Myers Squibb Company (NYSE: BMY) announced data from a three-year cohort (ETV-022/901, n=119), which showed BARACLUDE? (entecavir) suppressed viral load to undetectable levels in 90 percent of nucleoside-na?ve chronic hepatitis B e-antigen (HBeAg) positive patients at week 144 who continued on-treatment from week 96. In this cohort, undetectable HBV DNA levels were defined as less than 300 copies per mL of blood as measured by polymerase chain reaction (PCR). Suppression of viral load to undetectable levels is one of several measures of antiviral treatment response; a sustained, undetectable viral load is an important goal of chronic hepatitis B treatment. The results of this three-year cohort were presented today at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
New data presented today show patients taking pramipexole (Mirapexin?/ Sifrol?) can experience significant improvements in a broad range of symptoms associated with Restless Legs Syndrome (RLS).1 In an additional study presented today, pramipexole was also shown to be well tolerated in RLS patients affected by concomitant diseases, which are commonly experienced in this patient group.2 The results of the studies were presented at the 10th International Congress of Parkinson?s Disease and Movement Disorders (MDS) in Kyoto, Japan.
New data presented today from a meta-analysis* of nearly 1,300 Parkinson?s disease (PD) patients, indicate that pramipexole (Mirapexin?/Sifrol?) has a beneficial effect on depressive and motivational symptoms in PD.1 This confirms findings from previously published clinical trials,2,3,4 and is in addition to its established efficacy in controlling motor symptoms. These findings are of particular interest as mood symptoms in PD can affect up to 50 percent of the patient population.1,5 The data were presented at the 10th International Congress of Parkinson?s Disease and Movement Disorders (MDS) in Kyoto, Japan.
Berlex Oncology, a business unit of Berlex Laboratories, a U.S. affiliate of Schering AG, Germany (FSE: SCH; NYSE: SHR), today announced that a national clinical study is underway investigating a new approach to treating follicular B-cell lymphoma, a sub-type of non-Hodgkin?s lymphoma (NHL). NHL is the fifth most common form of cancer in the United States, with more than 56,000 new cases diagnosed each year. Follicular B-cell lymphoma is an indolent, or slow-growing, type of NHL that comprises approximately 30% of all diagnosed cases.
GlaxoSmithKline plc [NYSE:GSK, LSE:GSK] announced results from a global Phase II study of eltrombopag, an investigational non-peptide oral platelet growth factor. In this study of 74 hepatitis C patients with thrombocytopenia, (a condition where the blood has low platelet levels) more than 95% (p< 0.001) of patients treated with the highest dose of eltrombopag (75mg) had increased platelet counts. In addition, 71% - 91% of patients in all treatment groups were able to initiate antiviral therapy with pegylated interferon-α (IFN) and ribavirin, and 65% were able to be maintained on therapy.1 Full results from this Phase II study are being presented today at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, Massachusetts.
Pfizer Inc provided an update on the preliminary results of its torcetrapib/atorvastatin clinical trials in connection with the release of an American Heart Association abstract of a Phase 3 study in patients with heterozygous familial hypercholesterolemia (HeFH) that shows the drug significantly raising ‘good’ (HDL) cholesterol (56 percent) and additionally lowering ‘bad’ (LDL) cholesterol (27 percent) versus patients taking atorvastatin alone.
Lower back pain is one of the most common causes of job-related disability and why some people miss work. It is also the second most common neurological ailment in the United States, second only to headache. In fact, approximately 80% of adults in Western countries have, at some point, experienced lower back pain.